Modeling the heterogeneous intestinal absorption of propiverine extended-release

被引:4
|
作者
Weiss, Michael [1 ,2 ]
Sermsappasuk, Pakawadee [2 ]
Siegmund, Werner [3 ]
机构
[1] Univ Halle Wittenberg, Dept Pharmacol, D-06097 Halle, Saale, Germany
[2] Naresuan Univ, Fac Pharmaceut Sci, Phitsanulok, Thailand
[3] Ernst Moritz Arndt Univ Greifswald, Div Clin Pharmacol, Inst Pharmacol, Greifswald, Germany
关键词
Heterogenous absorption; Propiverine; Bioavailability; Dissolution time; DRUG ABSORPTION; EXPRESSION; IMMEDIATE; TRANSIT;
D O I
10.1016/j.ejps.2015.05.010
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Propiverine is a widely used antimuscarinic drug with bioavailability that is limited by intestinal first-pass extraction. To study the apparent heterogeneity in intestinal first-pass extraction, we performed a population analysis of oral concentration-time data measured after administration of an extended-release formulation of propiverine in ten healthy subjects. Using an inverse Gaussian function as input model, the assumption that the systemically available fraction increases as a sigmoidal function of time considerably improved the fit. The step-like increase in this fraction at time t = 3.7 h predicted by the model suggests that propiverine is predominantly absorbed in colon. A nearly perfect correlation was found between the estimates of bioavailability and mean dissolution time. (C) 2015 Elsevier B.V. All rights reserved.
引用
收藏
页码:133 / 137
页数:5
相关论文
共 50 条
  • [41] Selection of a hydrocodone bitartrate extended-release prototype with optimal tamper resistance and extended-release characteristics
    Darwish, M.
    Bond, M.
    Robertson, P.
    Tracewell, W.
    JOURNAL OF PAIN, 2013, 14 (04): : S74 - S74
  • [42] Colonoscopic method for estimating the colonic absorption of extended-release dosage forms in dogs
    Tajiri, Shinichiro
    Kanamaru, Taro
    Yoshida, Kazuhiro
    Hosoi, Yasue
    Fukui, Sachiko
    Konno, Tsutomu
    Yada, Shuichi
    Nakagami, Hiroaki
    EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2010, 75 (02) : 238 - 244
  • [43] ABSORPTION, GASTROINTESTINAL TRANSIT, AND TABLET EROSION OF FELODIPINE EXTENDED-RELEASE (ER) TABLETS
    ABRAHAMSSON, B
    ALPSTEN, M
    HUGOSSON, M
    JONSSON, UE
    SUNDGREN, M
    SVENHEDEN, A
    TOLLI, J
    PHARMACEUTICAL RESEARCH, 1993, 10 (05) : 709 - 714
  • [44] Trends in Extended-Release and Non-Extended-Release Buprenorphine Dispensing
    Stopka, Thomas J.
    Dalvi, Netrali
    Young, Leonard D.
    Shrestha, Shikhar
    Valerio, Danielle DeNufrio
    Walley, Alexander Y.
    JAMA NETWORK OPEN, 2025, 8 (04)
  • [45] The Abuse Potential of Remoxy®, an Extended-Release Formulation of Oxycodone, Compared with Immediate- and Extended-Release Oxycodone
    Setnik, Beatrice
    Roland, Carl L.
    Cleveland, Jody M.
    Webster, Lynn
    PAIN MEDICINE, 2011, 12 (04) : 618 - 631
  • [46] CORRELATION OF INVITRO RELEASE RATE AND INVIVO ABSORPTION CHARACTERISTICS OF 4 CHLORPHENIRAMINE MALEATE EXTENDED-RELEASE FORMULATIONS
    MOJAVERIAN, P
    RADWANSKI, E
    LIN, CC
    CHO, P
    VADINO, WA
    ROSEN, JM
    PHARMACEUTICAL RESEARCH, 1992, 9 (04) : 450 - 456
  • [47] Perioperative Management of Extended-release Buprenorphine
    Hickey, Thomas R. R.
    Henry, Jonathan T. T.
    Edens, Ellen L. L.
    Gordon, Adam J. J.
    Acampora, Gregory
    JOURNAL OF ADDICTION MEDICINE, 2023, 17 (01) : E67 - E71
  • [48] Guanfacine Extended-Release (Intuniv) for ADHD
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2010, 52 (1349): : 82 - 83
  • [49] Extended-release methylphenidate (Ritalin® LA)
    Lyseng-Williamson, KA
    Keating, GM
    DRUGS, 2002, 62 (15) : 2251 - 2259
  • [50] GASTRIC OBSTRUCTION WITH EXTENDED-RELEASE TABLETS
    HENNESSY, S
    FOGARTY, PM
    SCHULMAN, KA
    MIGNOTT, H
    DICP-THE ANNALS OF PHARMACOTHERAPY, 1991, 25 (06): : 678 - 679